Short Interest in Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Declines By 32.5%

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 744,500 shares, a decrease of 32.5% from the January 31st total of 1,103,100 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 7,445.0 days.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at $27.17 on Wednesday. The stock has a 50-day simple moving average of $26.15 and a 200 day simple moving average of $25.37. The company has a current ratio of 1.66, a quick ratio of 0.98 and a debt-to-equity ratio of 0.46. Hikma Pharmaceuticals has a 52 week low of $22.33 and a 52 week high of $28.92.

Hikma Pharmaceuticals Increases Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, March 21st will be paid a dividend of $0.48 per share. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.47. The ex-dividend date is Friday, March 21st.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.